NCT07644013Recruiting
Prospective Multicenter Registry Study of Multiple System Atrophy in China
Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited. This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 214 (estimated)
- First submitted
- 8 Jun 2026
- Start date
- 1 Jun 2025
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Peking University First Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07644013
What you commit to
- Study type: Observational
- Planned participants: 214
- From 1 Jun 2025 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.
Other illness
- Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.
- Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.
- Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.
- Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.
- Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.
Who the study is looking for
- Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
- Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
- Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
- Age between 40 and 75 years.
- Ability to provide informed consent or availability of a legally authorized representative when applicable.
Age in the registry: 40 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.